Literature DB >> 2156701

The role of carbohydrate in recombinant human erythropoietin.

E Tsuda1, G Kawanishi, M Ueda, S Masuda, R Sasaki.   

Abstract

1. Recombinant human erythropoietin has N-linked sugar [Tsuda et al., (1988) Biochemistry 27, 5646-5654]. Here we have demonstrated the presence of O-linked sugar (0.85 mol/mol erythropoietin) composed of sialic acid and Gal beta(1-3)GalNAc. 2. To investigate the role of these sugars, erythropoietins deglycosylated to different extents were prepared using specific glycosidases. Sugars are not essential for in vitro biological activity of erythropoietin, because the fully deglycosylated erythropoietin had the full activity when assayed with in vitro bioassay methods. Asialylation yielded erythropoietin with higher affinity to the receptor than the undigested hormone and therefore an increased in vitro activity. Although erythropoietin from which N-linked or total sugars were removed also had higher affinity for the receptor, their in vitro activity remained unchanged compared with that of the undigested erythropoietin for unknown reasons. On the other hand, removal of sialic acids or N-linked sugar abolished the in vivo biological activity completely, indicating that the presence of N-linked sugar with terminal sialic acids is required for the hormone to reach target sites; full deglycosylation resulted in total loss of the in vivo biological activity of erythropoietin. 3. Incubation of asialo-erythropoietin and fully deglycosylated recombinant human erythropoietin at 70 degrees C for 15 min decreased the biological activity to 35% and 11% of the initial activity, respectively, while the undigested erythropoietin lost no activity. Thus resistance of erythropoietin to thermal inactivation is largely due to the presence of sugars, and terminal sialic acids greatly contribute to the stability.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156701     DOI: 10.1111/j.1432-1033.1990.tb15417.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  49 in total

1.  Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.

Authors:  Austin W Boesch; James H Kappel; Alison E Mahan; Thach H Chu; Andrew R Crowley; Nana Y Osei-Owusu; Galit Alter; Margaret E Ackerman
Journal:  Biotechnol Bioeng       Date:  2018-02-01       Impact factor: 4.530

2.  Solid phase synthesis of the fibronectin glycopeptide V(Gal beta 3GalNAc alpha)THPGY, its beta analogue, and the corresponding unglycosylated peptide.

Authors:  B Lüning; T Norberg; C Rivera-Baeza; J Tejbrant
Journal:  Glycoconj J       Date:  1991-12       Impact factor: 2.916

3.  Related effects of cell adaptation to serum-free conditions on murine EPO production and glycosylation by CHO cells.

Authors:  François Lefloch; Bertrand Tessier; Sébastien Chenuet; Jean-Marc Guillaume; Pierre Cans; Jean-Louis Goergen; Annie Marc
Journal:  Cytotechnology       Date:  2006-12-29       Impact factor: 2.058

Review 4.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

5.  Rationalizing 5000-fold differences in receptor-binding rate constants of four cytokines.

Authors:  Xiaodong Pang; Sanbo Qin; Huan-Xiang Zhou
Journal:  Biophys J       Date:  2011-09-07       Impact factor: 4.033

6.  Biological and physicochemical characterization of recombinant human erythropoietins fractionated by Mono Q column chromatography and their modification with sialyltransferase.

Authors:  K Morimoto; E Tsuda; A A Said; E Uchida; S Hatakeyama; M Ueda; T Hayakawa
Journal:  Glycoconj J       Date:  1996-12       Impact factor: 2.916

Review 7.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

Review 8.  Survival and proliferative roles of erythropoietin beyond the erythroid lineage.

Authors:  Constance Tom Noguchi; Li Wang; Heather M Rogers; Ruifeng Teng; Yi Jia
Journal:  Expert Rev Mol Med       Date:  2008-12-01       Impact factor: 5.600

9.  Development of glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with D-galactose monosaccharide: biological activities in vivo.

Authors:  S Nabeshima; T Chiba; Y Takei; A Ono; K Moriya; K Onozaki
Journal:  Glycoconj J       Date:  1998-05       Impact factor: 2.916

Review 10.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.